Literature DB >> 6434791

Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis.

R M Pérez-Ayuso, V Arroyo, J Camps, A Rimola, J Gaya, J Costa, F Rivera, J Rodés.   

Abstract

Plasma antidiuretic hormone (ADH) and urinary prostaglandin E2 excretion (UPGE2V) were measured in basal conditions, after water restriction, and after water-loading in 10 normal subjects (free water clearance after the water load, CH2O, 9.6 +/- 0.8 ml/min) and in 27 patients with cirrhosis and ascites (13 with a positive CH2O: 3.6 +/- 0.5; 14 with a negative CH2O: -0.37 +/- 0.007). Plasma ADH and UPGE2V were significantly increased in patients with a positive CH2O as compared with normal subjects. Patients with a negative CH2O showed a significantly higher plasma ADH and a lower UPGE2V and GFR than did normal subjects and patients with the positive CH2O. In 18 additional subjects (6 normal and 12 with cirrhosis, ascites, and a positive CH2O) submitted to a sustained water overload, the i.v. administration of 450 mg of lysine acetylsalicylate (LAS) induced a marked reduction of UPGE2V, but it had no effect on plasma ADH. LAS did not alter GFR and CH2O in normal subjects; however, it reduced CH2O in all the 12 patients (from 5.1 +/- 0.4 to 0.6 +/- 0.3) and the GFR in only 6 of these patients. These results suggest (a) that renal PGE2 plays an important role in the maintenance of water excretion in cirrhosis with ascites, and (b) that impaired ability to dilute the urine in cirrhosis may be a consequence of the simultaneous occurrence of impaired renal hemodynamics, nonostomic hypersecretion of ADH, and reduced renal production of PGE2.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6434791     DOI: 10.1038/ki.1984.136

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  18 in total

Review 1.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

Review 2.  The endocrinology and pathophysiology of alcoholic cirrhosis and functional renal failure--a review.

Authors:  E S Domurat; A N Elias
Journal:  J Natl Med Assoc       Date:  1992-02       Impact factor: 1.798

3.  Treatment of ascites in patients with cirrhosis of the liver.

Authors:  V Arroyo; P Ginés; J Rodés
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

4.  Effect of captopril on renin and blood pressure in cirrhosis.

Authors:  B Stanek; F Renner; A Sedlmayer; K Silberbauer
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  The role of renal prostaglandin E as a possible modulator of cyclic AMP production in nephrotic syndrome.

Authors:  S Túri; Z Havass; T Bodrogi
Journal:  Int Urol Nephrol       Date:  1986       Impact factor: 2.370

Review 6.  Management of hepatorenal syndrome in patients with cirrhosis.

Authors:  Vicente Arroyo; Javier Fernández
Journal:  Nat Rev Nephrol       Date:  2011-08-09       Impact factor: 28.314

7.  Glucose-induced changes in renal haemodynamics in proteinuric type 1 (insulin-dependent) diabetic patients: inhibition by acetylsalicilic acid infusion.

Authors:  S De Cosmo; K Earle; A Morocutti; J Walker; P Ruggenenti; G Remuzzi; G C Viberti
Journal:  Diabetologia       Date:  1993-07       Impact factor: 10.122

8.  Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis.

Authors:  Sakib K Khalid; Jill Lane; Victor Navarro; Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2009-04-24       Impact factor: 11.382

Review 9.  Pharmacotherapy of ascites associated with cirrhosis.

Authors:  P Ginès; V Arrovo; J Rodés
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

10.  Renal failure in children with hepatic failure undergoing liver transplantation.

Authors:  D Ellis; E D Avner; T E Starzl
Journal:  J Pediatr       Date:  1986-03       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.